Recombinant Human Keratin, Type I Cytoskeletal 19 (KRT19) Protein (His)

Name: Recombinant Human Keratin, Type I Cytoskeletal 19 (KRT19) Protein (His)
Brand: Beta LifeScience
SKU: BLC-00064P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Keratin, Type I Cytoskeletal 19 (KRT19) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P08727
Target Symbol	KRT19
Synonyms	40 kDa keratin intermediate filament; CK 19; CK-19; CK19; Cytokeratin 19; Cytokeratin-19; K19; K1C19_HUMAN; K1CS; Keratin 19; Keratin type I 40 kD; Keratin type I 40kD; Keratin type I cytoskeletal 19; Keratin, type I cytoskeletal 19; Keratin, type I, 40 kd; Keratin-19; KRT19; MGC15366
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	MTSYSYRQSSATSSFGGLGGGSVRFGPGVAFRAPSIHGGSGGRGVSVSSARFVSSSSSGAYGGGYGGVLTASDGLLAGNEKLTMQNLNDRLASYLDKVRALEAANGELEVKIRDWYQKQGPGPSRDYSHYYTTIQDLRDKILGATIENSRIVLQIDNARLAADDFRTKFETEQALRMSVEADINGLRRVLDELTLARTDLEMQIEGLKEELAYLKKNHEEEISTLRGQVGGQVSVEVDSAPGTDLAKILSDMRSQYEVMAEQNRKDAEAWFTSRTEELNREVAGHTEQLQMSRSEVTDLRRTLQGLEIELQSQLSMKAALEDTLAETEARFGAQLAHIQALISGIEAQLGDVRADSERQNQEYQRLMDIKSRLEQEIATYRSLLEGQEDHYNNLSASKVL
Expression Range	1-400aa
Protein Length	Full length
Mol. Weight	48.2 kDa
Research Area	Signal Transduction
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.
Protein Families	Intermediate filament family
Database References	HGNC: 6436 OMIM: 148020 KEGG: hsa:3880 STRING: 9606.ENSP00000355124 UniGene: PMID: 30037371 CYFRA 21-1 assessed at the end of RT or ChT seems to be a prognostic marker for tumor response. A high concentration of CYFRA 21-1 after treatment increases the risk of death. CYFRA 21-1 might be suggested in the monitoring of carcinomas of head and neck cancer (HNC). PMID: 28604997 the modulation of KRT19 expression could be involved in cancer stem cell reprogramming and drug sensitivity. PMID: 29747452 High expression of CK-19 is associated with intrahepatic cholangiocarcinoma. PMID: 29513894 KRT19 intracellularly binds to HER2, playing a critical role in HER2 activation PMID: 28008968 The combined use of CK19 and CD56 is helpful in discriminating papillary thyroid carcinoma and its variants from other mimicking thyroid lesions. PMID: 28214214 CYFRA 21-1 can be useful as a tumor marker for evaluating tumor progression and treatment efficacy in patients with extramammary Paget's disease. PMID: 28150330 YAP1 activation was more commonly found in CCAs than in pure HCCs. However, a differing pattern of YAP1 expression between cHC-CCAs and CK19(+) HCCs and the poor prognosis of YAP1 positive hepatic carcinomas suggests that YAP1 may have a preferential role in aggressive tumor behavior, rather than in the determination of cellular lineage in hepatic carcinomas PMID: 28645247 Circulating tumor cells expressing cytokeratin and tumor-initiating cell markers, including ALDH, CD133, and CD44, were identified in patients with pancreatic adenocarcinoma. These TIC-like CTCs were associated with poor prognosis after surgical resection and with an increased incidence of tumor recurrence PMID: 27789528 Aberrant decreased miR-26a could promote cell proliferation by regulating KRT19 which plays important role in the pathogenesis of cholangiocarcinoma. PMID: 27833076 The detection of TK1 combined with that of cytokeratin-19 fragment (CYFRA21-1), CEA or NSE increased the diagnostic value of TK1 for lung squamous cell carcinoma, adenocarcinoma and small cell lung cancer, respectively. PMID: 29247745 Our results are of special importance against the background that CK19 positive carcinomas revealed a significantly poorer prognosis and therefore emphasize its prognostic and possible diagnostic role in tongue cancer. PMID: 27764819 (18)F-FDG-PET can be used to predict K19 expression in hepatocellular carcinoma and should thereby aid in the development of novel therapeutic strategies targeting K19(+) hepatocellular carcinoma cancer stem cells PMID: 27663597 Immunohistochemical assessment of both CK19 and SCCAg status in histologically negative sentinel lymph nodes may be a valuable approach for predicting recurrence and survival after curative surgery for cervical squamous cell carcinoma. PMID: 27654256 Positive CK-19 expression can be used as a predictor of poor prognosis of PNET PMID: 29136022 Data suggest that high cytokeratin 19 (CK19) levels in peripheral blood may independently predict non-sentinel lymph node (nSLN) metastasis in breast cancer patients. PMID: 27105542 Findings provide evidence that K19 expression is inducible in human hepatocellular carcinoma as a sign of tumor progression. PMID: 28783171 Urine levels of COL4A1, COL13A1, the combined values of COL4A1 and COL13A1 (COL4A1 + COL13A1), and CYFRA21-1 were significantly elevated in urine from patients with BCa compared to the controls. A high urinary COL4A1 + COL13A1 was found to be an independent risk factor for intravesical recurrence. PMID: 28837258 CK19 and carcinoembryonic antigen may be involved in lymph node metastasis and poor prognosis in patients with gastriccardia cancer PMID: 28293089 The study has confirmed the preservation of CK19 protein expression in breast cancer cells after neoadjuvant therapy. On the basis of these results, quantification-based methods such as the one-step nucleic acid amplification (OSNA) CK19 assay, could be an accurate tool with which to analyse the sentinel nodes, regardless of whether they had been obtained before or after treatment. PMID: 26708058 Serum CYFRA 21-1 level may be a predictive factor for patients with non-small cell lung cancers treated with EGFR-TKIs, regardless of EGFR mutation status. PMID: 28982900 Data suggest that keratin (K) 19 (K19) may be a drug target for the treatment of K19-positive hepatocellular carcinoma (HCC). PMID: 27863477 Combination of the two tumor markers, CEA and CYFRA21-1, is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients PMID: 28870944 Results suggest that positive expression of CK19 mRNA and TK1 protein is closely correlated with poor prognosis in advanced gastrointestinal cancer. PMID: 27625087 GPC3 and KRT19 overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC. PMID: 27689616 Data show that sixty one patients with a high cytokeratin 19 fragment (CYFRA 21-1) level had statistically shorter progression-free and overall survival than 39 patients with a normal CYFRA 21-1 level . PMID: 28179355 Data indicate that serum tumor markers showed significant shorter 3-year progression-free survival (PFS) in higher levels compared to lower levels for S-CYFRA 21-1 (cytokeratin 19 fragment), S-SCCA and S-CEA. PMID: 26432331 Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA PMID: 27097811 Peritumoral ductular reaction was more abundant and proliferative in CK19+ hepatocellular carcinoma patients, with higher level of nuclear translocation of beta-catenin. PMID: 27049492 BALF and serum NSE, CEA, and CYFRA21.1 elevated in lung cancer, which had prompt value for pathology, especially significant for BALF. PMID: 27072263 Significant levels of CEA, CYFRA 21-1, NSE, and TSGF were detected in the serum. The amounts found were useful for diagnosing non-small cell lung cancer (NSCLC) patients who depended on the currently limited biomarker development. PMID: 27072222 The cytologic tumor marker c-CYFRA was positively associated with EGFR mutations in non-small cell lung cancer (NSCLC). EGFR mutation-positive NSCLCs have relatively lower glycolysis compared with NSCLCs without EGFR mutation PMID: 26979333 Results show that serum miR21 could serve as an important marker for auxiliary diagnosis of early non-small cell lung cancer (NSCLC), while joint detection of serums miR21 and CYFRA21-1 levels could improve diagnostic efficiency. PMID: 26880855 Positive staining for CK19 suggests a possible LPC origin of the EpCAM positive hepatocellular carcinoma . PMID: 26609030 Increased Expression of K19 mRNA is associated with Recurrence After Curative Resection of Hepatocellular Carcinoma. PMID: 25791790 Patients with CK19 positivity showed a higher prevalence of microvessel invasion than those without CK19. PMID: 26212571 We report results of the studies relating to fabrication of a non-invasive, label-free and an efficient biosensing platform for detection of the oral cancer biomarker (CYFRA-21-1). PMID: 26657594 Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable. PMID: 26333429 Data show that serum neuron-specific enolase, cytokeratin 19 fragment 21-1, pro-gastrin-releasing peptide, squamous cell carcinoma antigen, tissue inhibitor of metalloproteinase-1, and human epididymis protein 4 are not associated with brain metastases. PMID: 26730601 CK19 expression was measured in hepatocellular carcinoma at different stages and correlated with prognosis. CK19+/GPC3+ HCC has the highest risk of intrahepatic metastasis, microvascular invasion, regional lymph node involvement, and distant metastasis. PMID: 26977595 CK19 staining was found in hepatic hydatidosis patients with and without biliary fistula. PMID: 27141570 When confirmed by a low alpha-fetoprotein concentration (<400 mug/L), CK-19 expression in is an additional valuable indicator of early recurrence, distant metastasis, and poor prognosis in HBV-positive patients PMID: 26588210 Study confirms the prognostic significance of K19 expression in Caucasian patients with hepatocellular carcinoma. PMID: 26011233 High serum levels of CYFRA 21-1 are associated with oral squamous cell carcinoma. PMID: 26292957 K19 is a new cancer stem cell marker associated with epithelial mesechymal transformation and TGFb/Smad signaling. PMID: 25820415 Elevation of serum CYFRA21-1 is associated with Non-small Cell Lung Cancer. PMID: 26163610 Postoperative CK19-2G2 concentration may be an indicator of prognosis. An increase after the initial drop in CK19-2G2 concentration after surgery may indicate a poor prognosis. PMID: 26002573 CK19 and HBME-1 were significantly expressed more in papillary carcinoma as compared to follicular carcinoma PMID: 26503236 CK19 mRNA expression in peripheral blood was evaluated by qRT-PCR as an index of circulating tumor cells in 15 cases of HER-2-positive breast cancer and 18 cases of HER2-negative breast cancer PMID: 25867356 CK19 proved to be a sensitive marker to identify yolk sac tumours of the testis and to distinguish them from other germ cell tumours. PMID: 25889715

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.